Literature DB >> 12047268

Review article: dyspepsia: how to manage and how to treat?

N J Talley1.   

Abstract

Recent guidelines for dyspepsia, defined as pain or discomfort centred in the upper abdomen, emphasize that in younger patients with no alarm features and not taking nonsteroidal anti-inflammatory drugs, testing for Helicobacter pylori and treatment of the infection if present is a standard of care. If H. pylori is not present, empirical management (e.g. acid suppression) is often prescribed. It is further recommended that if patients relapse or fail to respond to treatment then upper endoscopy be undertaken. However, these guidelines have become controversial for a number of reasons. Firstly, the prevalence of H. pylori infection is falling as is the incidence of peptic ulcer disease due to the infection. Idiopathic peptic ulcer disease is also being increasingly recognized. Furthermore, the cost-effectiveness of endoscoping treatment failures has been questioned, as the yield is low and patient management is usually not altered. Finally, it remains controversial whether the treatment of H. pylori infection in functional dyspepsia is of value, and two recent high quality meta-analyses have reached diametrically opposite conclusions. Alternative strategies, such as initially treating with acid suppression and then considering H. pylori infection in those who fail have been suggested, as has in low H. pylori prevalent regions the abandonment of a test-and-treat strategy. However, appropriate management trials of these alternative strategies in primary care are lacking. The management of patients with functional dyspepsia who fail initial antisecretory therapy is now difficult; prokinetics have fallen into some disrepute. Tricyclic antidepressants (at a low dose) may be useful in a subset, but adequate trials are lacking.

Entities:  

Mesh:

Year:  2002        PMID: 12047268     DOI: 10.1046/j.1365-2036.16.s4.12.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  DA-9601 for erosive gastritis: results of a double-blind placebo-controlled phase III clinical trial.

Authors:  Sang-Yong Seol; Myung-Hwan Kim; Jong-Sun Ryu; Myung-Gyu Choi; Dong-Wook Shin; Byoung-Ok Ahn
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

2.  Who benefits from Helicobacter pylori eradication?

Authors:  Brendan C Delaney
Journal:  BMJ       Date:  2006-01-28

Review 3.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial.

Authors:  J Athene Lane; Liam J Murray; Sian Noble; Matthias Egger; Ian M Harvey; Jenny L Donovan; Prakash Nair; Richard F Harvey
Journal:  BMJ       Date:  2006-01-20

5.  Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial.

Authors:  A T Lassen; J Hallas; O B Schaffalitzky de Muckadell
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

6.  Audit of Helicobacter pylori Testing in Microbiology Laboratories in England: To Inform Compliance with NICE Guidance and the Feasibility of Routine Antimicrobial Resistance Surveillance.

Authors:  Rosalie Allison; Donna M Lecky; Megan Bull; Kim Turner; Gauri Godbole; Cliodna A M McNulty
Journal:  Int J Microbiol       Date:  2016-10-18

7.  Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review.

Authors:  Javier P Gisbert; Xavier Calvet
Journal:  Clin Transl Gastroenterol       Date:  2013-03-28       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.